{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination creates an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.",
          "line_ref": "L11"
        },
        {
          "quote": "Type I interferon response score (normalized units): 3.1",
          "line_ref": "L31"
        },
        {
          "quote": "PD-L1 expression fold-change in tumor tissue: 2.4x",
          "line_ref": "L32"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination leads to broader antigen display through expansion of the MHC-I-presented peptide repertoire.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome: 62.3%",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome: 40.6%",
          "line_ref": "L29"
        }
      ],
      "caveat": "Results may vary depending on the specific tumor model system used."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling is necessary for the observed tumor sensitization effect.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Experiments were conducted in controlled preclinical models and may not fully capture human tumor heterogeneity."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic patients receiving ICI treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value: p=0.01",
          "line_ref": "L30"
        },
        {
          "quote": "aligns with better outcomes in the retrospective human cohort",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely and vaccination timing relative to ICI initiation varied across patients."
    }
  ]
}
